Suraksha Diagnostic Ltd Share Price

Financial Inclusion Milestone: PMJDY Touches 12-Year Mark

The Pradhan Mantri Jan Dhan Yojana (PMJDY), launched on August 28, 2014, has completed 12 years as the world’s largest financial inclusion program, fundamentally expanding formal banking access across India. As of August 19, 2026, the initiative has reached 59.09 crore PMJDY accounts with cumulative deposits totaling ₹3.17 lakh crore ($33.37 billion). The scheme emphasizes demographic and geographic reach, with women accounting for 55.7% (32.92 crore) of all account holders and rural or semi-urban areas representing 77.8% (45.95 crore) of total accounts. Beyond basic savings accounts, the platform has accelerated digital payments and financial protection through the issuance of 41.29 crore RuPay cards, complemented by ₹2 lakh in accident insurance coverage, a ₹10,000 overdraft facility, and integration with the Jan Suraksha insurance schemes. Central to this transformation is the Jan-Dhan–Aadhaar–Mobile (JAM) Trinity, which uses PMJDY as its baseline infrastructure to enable direct, transparent, and leakage-proof welfare benefit transfers directly to beneficiaries. Over the 12-year period (August 2015 to August 2026), total deposits grew nearly 12.8-fold while total accounts expanded 2.3-fold, driving a 3.4-fold increase in average deposits per account to ₹5,356. By bridging access to formal credit mechanisms, micro-pensions, and enterprise credit options like MUDRA loans, the scheme continues to strengthen savings habits, financial resilience, and economic empowerment among historically underserved populations.

Suraksha Diagnostic: Group CFO K.S. Ravindra Resigns • 👤 CFO Exit: Group Chief Financial Officer (KMP) K.S. Ravindra has resigned citing personal reasons. • 📅 Last Working Day: He will step down on or before 31 May 2026. • 📝 No Other Reasons: Company confirmed no material issues behind the resignation. • 🤝 Acknowledgement: Board appreciated his contribution during tenure. 🟡 Impact: Neutral to Slightly Negative Senior leadership exit may create near-term uncertainty, but limited impact as resignation is for personal reasons and transition time is available.

Suraksha Diagnostic Ltd’s share price on 21-Jan can be attributed primarily to a short-term technical rebound following a period of decline, combined with encouraging fundamental indicators. The stock’s outperformance relative to the sector and benchmark indices, alongside a strong intraday high, suggests renewed investor interest. Underlying this price movement are the company’s solid financial metrics, including low leverage, substantial profit growth, and a fair valuation framework. The presence of institutional shareholders further bolsters confidence in the company’s prospects. While longer-term returns remain negative, the recent price action may reflect early recognition of the company’s improving earnings trajectory and financial health. Investors should monitor whether the stock can sustain gains and break above its longer-term moving averages to confirm a more durable recovery. For now, the combination of technical recovery and fundamental strength explains the stock’s rise on 21-Jan.

Life Insurance Corporation of India (LIC) launches 2 new products effective Oct 15, 2025

• LIC’s Jan Suraksha — Non-Participating, Non-Linked, Individual Savings Life Micro Insurance Plan designed to offer affordable protection & savings for lower-income groups. • LIC’s Bima Lakshmi — Non-Participating, Non-Linked, Individual Savings Life Plan aimed at providing life cover along with guaranteed savings benefits. Both plans are tailored for the domestic market, reinforcing LIC’s focus on expanding inclusive insurance coverage across India.

Yes Bank Audit Flags Governance Lapses in ₹500 Crore Loan Sale to Suraksha ARC

A recent internal audit has raised serious questions about a ₹500 crore non-performing asset (NPA) sale by

Suraksha Diagnostic, a microcap company in the healthcare services sector, has reported its financial results for the quarter ending June 2025 on August 8, 2025. The company experienced flat financial performance, with its score declining to -2 from -1 over the past three months. On a positive note, Suraksha Diagnostic achieved its highest quarterly net sales in the last five quarters, totaling Rs 72.59 crore. The operating profit also reached a peak of Rs 23.75 crore during the same period, indicating a favorable near-term trend. Additionally, the profit before tax (PBT) grew by 23.1% compared to the average of the previous four quarters, amounting to Rs 11.56 crore. Conversely, the company faced challenges with rising interest costs, which increased by 31.07% quarter on quarter, reaching Rs 2.70 crore, the highest in the last five quarters. This rise in interest expenses has led to a decline in the operating profit to interest ratio, now at its lowest level of 8.80 times in the last five quarters, indicating a deteriorating ability to manage interest payments.